Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Accured Expenses: 2011-2024

Historic Change in Accured Expenses for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to -$1.1 million.

  • Adma Biologics' Change in Accured Expenses fell 15.71% to -$221,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 56.46%. This contributed to the annual value of -$1.1 million for FY2024, which is 115.19% down from last year.
  • According to the latest figures from FY2024, Adma Biologics' Change in Accured Expenses is -$1.1 million, which was down 115.19% from $7.5 million recorded in FY2023.
  • Adma Biologics' Change in Accured Expenses' 5-year high stood at $8.3 million during FY2021, with a 5-year trough of -$1.1 million in FY2024.
  • In the last 3 years, Adma Biologics' Change in Accured Expenses had a median value of $7.5 million in 2023 and averaged $4.6 million.
  • In the last 5 years, Adma Biologics' Change in Accured Expenses soared by 145.19% in 2021 and then plummeted by 115.19% in 2024.
  • Adma Biologics' Change in Accured Expenses (Yearly) stood at $3.4 million in 2020, then surged by 145.19% to $8.3 million in 2021, then dropped by 9.68% to $7.5 million in 2022, then fell by 0.05% to $7.5 million in 2023, then crashed by 115.19% to -$1.1 million in 2024.